Scottsdale, Arizona, United States, November 19, 2026
Innovative Health, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) to reprocess the OCTARAY™ Mapping Catheter, an advanced electrophysiology device originally manufactured by Biosense Webster, part of Johnson & Johnson MedTech. The announcement marks the company’s 52nd FDA clearance and expands the range of single-use medical devices that can be included in hospital reprocessing programmes. OCTARAY is used during electrophysiology procedures to map the heart’s electrical activity, helping physicians assess cardiac electrical signals and identify areas associated with abnormal heart rhythms. According to Innovative Health, it is currently the only medical-device reprocessing company with FDA clearance to reprocess this particular catheter. The new regulatory clearance is expected to provide hospitals with another option for managing the costs and waste associated with advanced electrophysiology equipment. It also represents a development in the regulated medical-device reprocessing sector, where specialised engineering, cleaning, sterilisation and performance validation are required before previously used devices can be processed for another clinical use. The announcement highlights the growing role of reprocessing programmes in supporting hospital resource management while maintaining access to specialised cardiac technologies.
FDA Clearance Expands OCTARAY Reprocessing Options
The OCTARAY Mapping Catheter is an advanced cardiac electrophysiology device designed to capture and map electrical activity within the heart. Electrophysiology specialists use mapping catheters during procedures to investigate abnormal electrical pathways and support the diagnosis and treatment of cardiac arrhythmias. The device was originally developed and manufactured by Biosense Webster, a Johnson & Johnson MedTech company known for its electrophysiology technologies. The FDA clearance granted to Innovative Health specifically covers the company’s reprocessing of the OCTARAY catheter. This distinction is important because the announcement does not describe a new clearance for the original device or a new clinical indication. Instead, it authorises Innovative Health to reprocess a device originally labelled for single use under its validated regulatory framework. The clearance expands the options available to hospitals that already use OCTARAY technology in their electrophysiology laboratories. Innovative Health stated that the authorisation makes it the only reprocessor currently cleared to reprocess this advanced mapping catheter. For healthcare facilities, the additional option may help reduce expenditure on selected medical devices while retaining access to the mapping technology used by their clinical teams.
Engineering and Sterilisation Validation Support Reuse
Obtaining FDA clearance to reprocess a single-use medical device requires extensive technical and regulatory work. According to Innovative Health, its process involves engineering assessments, cleaning validation, sterilisation validation, testing and inspection procedures. These steps are important because a device that has already been used must undergo controlled processing to ensure that it meets applicable requirements before it can be made available for another use. Reprocessing programmes must address potential contamination, material integrity and device performance, particularly for complex devices that incorporate advanced components and sensing technologies. Electrophysiology mapping catheters present specialised challenges because their functionality is important for collecting accurate electrical information during cardiac procedures. The company said its focus on cardiology and electrophysiology has helped it develop expertise in the technologies used in these clinical environments and the requirements associated with their reprocessing. The newly announced authorisation is the company’s 52nd FDA clearance, reflecting its continuing investment in expanding its portfolio of eligible devices. Regulatory clearance is device- and process-specific; it should not be interpreted as blanket permission to reuse every single-use catheter or other medical device. Hospitals must follow the applicable labelling, processing requirements and clinical protocols for each authorised reprocessed product.
Reprocessing Supports Hospital Cost and Waste Management
Innovative Health said the OCTARAY clearance creates an opportunity for hospitals to expand their electrophysiology reprocessing programmes and potentially reduce medical-device costs and waste. Advanced electrophysiology procedures can require specialised equipment, and the ability to reprocess eligible devices may help healthcare facilities manage purchasing expenses. Reprocessing may also reduce the number of devices discarded after a single use, contributing to efforts to improve resource utilisation in hospital settings. The company recently introduced The Reprocessing Performance Benchmark, a report intended to help electrophysiology leaders assess their programmes and identify opportunities for improvement. The OCTARAY clearance complements this initiative by adding another advanced device to the company’s reprocessing portfolio. Innovative Health’s strategy focuses on cardiology and electrophysiology, areas where device complexity and specialised clinical requirements make technical validation particularly important. The announcement also reflects a wider healthcare industry interest in balancing access to advanced medical technologies with cost control and environmental considerations. However, the financial and environmental benefits will depend on individual hospital purchasing patterns, reprocessing volumes and implementation practices. With its latest FDA clearance, Innovative Health is expanding the range of electrophysiology devices available through its regulated reprocessing programme and creating another option for hospitals using OCTARAY mapping technology.
Source: Innovative Health press release



